Oncosil Medical Ltd · ASX:OSL
Oncosil Medical — Investor Presentation (June 2018)
24 slides from Oncosil Medical's investor presentation, Jun 4, 2018
Slide 1: Company Update: Advancing Pancreatic Cancer Treatment
Company Update ASX.OSL June 2018 Advancing Pancreatic Cancer Treatment OncoSil Medical 1
Slide 2: OncoSil Medical | Investment Highlights
OncoSil Medical | Investment Highlights 1 Clear Commercialising a breakthrough implantation radiation mission treatment for Pancreatic cancer 2 Current and previous clinical studies demonstrate: Excellent Local Disease Control Sound Significant reduction in tumour size and volume science Excel
Slide 3: OncoSil Medical
OncoSil Medical OncoSilTM is a first in class medical device for the treatment of unresectable locally advanced pancreatic cancer First in class technology Share price performance (1 year) Proprietary brachytherapy (internal radiation) medical Share price (acps) Volume (m) device 20 12 Cancer is
Slide 4: About the OncoSil device
About the OncoSilTM device An implantable radiotherapy medical device targeting pancreatic cancer OncoSilTM is a single-use brachytherapy device Delivered through microparticles: 30-micron silicon particles contain beta-emitting Phosphorus-32 (32P) OncoSilTM Microparticles are inserted directly into
Slide 5: Implantation procedure
Implantation procedure Studies continue to show the device implantation is technically straightforward Endoscope guided into the OncoSil™ injected OncoSilTM dose is upper intestine directly into the suspended in a tumour Using CT or real-time imaging, specially formulated the needle is guided into t
Slide 6: Real-Time Visualisation
Real-Time Visualisation Needle Positioning in Pancreatic Mass via Endoscopic Ultrasound (EUS) Needle positioning OncoSil™ deposition OncoSil Medical BSI Meeting XXXX 66
Slide 7: OncoSil at a potential value inflection point
OncoSil at a potential value inflection point The Company is well positioned to realise value of OncoSil™ device Current focus Before 2015: 2016 to 2018: 2018 onwards: Demonstrate Satisfy regulatory Path to potential obligations commercialisation 4 studies show Secured US FDA IDE approval Secu
Slide 8: Clinical pathway overview
Clinical pathway overview PanCO and OncoPaC-1 to inform future studies Future focus Phases: Current focus Studies to drive clinical adoption (EU & global) 2 concurrent trials, targeting 65 patients total and secure US FDA approval Trials: PanCO – 45 patients Company exploring clinical study options
Slide 9: PanCO study – positive results to date
PanCO study – positive results to date Positive clinical data on 20 patients (at Week 8) and 20 patients (at Week 16) Study progress overview 47 patients enrolled1 36 patients implanted1 Disease Control Rate (DCR) of 100% Partial Response – a reduction (Week 8) and 87% (Week 16) in tumour longest
Slide 10: Tumours successfully resected
Tumours successfully resected Recap of study context Study population drawn from patients with To date, 5 out of 20 implanted patients have undergone unresectable locally surgical resection with curative intent (undergoing the advanced pancreatic cancer Whipple procedure) Primary objective of
Slide 11: Substantial tumour volumetric reduction
Substantial tumour volumetric reduction Revamped leadership team Best tumour volumetric change in first 20 implanted patients 18 of 20 patients (90%) demonstrated reduction in 60% tumour volume of at least 20% 40% from baseline % change from baseline 20% (20%) * (40%) * (60%) † * * (80%) * * * * (10
Slide 12: Significant opportunity for OncoSil
Significant opportunity for OncoSil Current available treatment for pancreatic cancer The opportunity for OncoSil Surgery (resection), if diagnosed early enough Only two drugs to have made Chemotherapy (Gemcitabine and Abraxane) significant improvements in pancreatic cancer in over 20 years: ⎼
Slide 13: Positive reception at key conferences
Positive reception at key conferences Early study data presented at European Association of Nuclear Medicine (EANM) Annual Congress and European Society of Medical Oncology (ESMO) The EANM is the largest organisation dedicated to Nuclear Medicine in Europe ESMO is Europe’s leading non-profit med
Slide 14: Partnering with leading cancer centres
Partnering with leading cancer centres 15 leading cancer centres participating in Global Pancreatic Cancer clinical programme Region Centre MD Anderson, Texas Johns Hopkins, Maryland Moffit Cancer Centre Florida Cedars Sinai Hospital, LA Guy’s & St Thomas’, London University of Leicester Hammersmith
Slide 15: Clear pathway to commercialisation
Clear pathway to commercialisation Strategic partners provide multiple paths to market to optimise value Well positioned for commercialisation Potential paths to market Broad technology platform Treatment for multiple solid tumours Strategic licensing partners in all key geographies Excellent clinic
Slide 16: Target markets
UK(Launch market) 1,2 Pancreatic cancer 8,747 Liver cancer 4,186 European Union1,2 Pancreatic cancer 79,331 Liver cancer 51,785 Target markets Annual incidence China1,2 Global opportunity United States 1,2 Pancreatic cancer 65,727 Liver cancer 351,000 Pancreatic cancer US>$2.0bn Pancreatic cancer 42
Slide 17: Global Commercial opportunity in excess of $2bn
Global Commercial opportunity in excess of $2bn 130,000 cases per year in US+EU alone: more than 70,000 of these could benefit from OncoSil More than 70,000 relevant Locally OncoSil™ provides a suitable treatment to patients in EU and US alone advanced control the growth of the primary tumour and pr
Slide 18: OncoSil's commercial path has precedent
OncoSil’s commercial path has precedent Sirtex provides a useful case study to demonstrate the potential commercial journey for OncoSil due to similarities in addressable market 24-Aug-00 5-Mar-02 Listed on the ASX with Phase II FDA approval for SIR-spheres achieved and Phase III clinical trials com
Slide 19: Sector M&A trends
Sector M&A trends Over A$2bn of acquisitions in February 2018 highlights attraction of early-stage Australian biotech to global pharmaceutical players Acquiree Acquirer Consideration A$1.6 billion1 A$502 million1 A$120 million1 Date 30 Jan 2018 22 Feb 2018 6 Feb 2018 Premium 60% (1 month VWAP)2 160%
Slide 20: Board of Directors
Board of Directors • Board and management are experienced leaders in the pharmaceutical and medical device space, having held senior positions at Cochlear (ASX:COH), Sirtex Medical (ASX:SRX), ABIVAX, Baxter International, Roche and more • Extensive leadership experience guiding products from clinica
Slide 21: Highly experienced management team
Highly experienced management team Revamped Medical (ASX:SRX) leadership • Management team experienced leaders team in the medical device space having held senior positions at Sirtex • Extensive leadership experience in clinical studies, commercialisation and manufacturing & operations Mr Daniel Ken
Slide 22: Key catalysts in CY 2018
Key catalysts in CY 2018 Revamped leadership team Target submission of 16 week 20 patient supplemental data to BSI by 31-May-18 CE Mark Target CE Mark certification Target EU first sales Continued recruitment into the Global Pancreatic Cancer clinical study Global Pancreatic program, (PanCO
Slide 23: Important notice
Important notice This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (OncoSil or the Company) to provide an overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presentation and the informati
Slide 24: Daniel Kenny, CEO & Managing Director
Daniel Kenny CEO & Managing Director E: daniel.kenny@oncosil.com.au OncoSil Medical Ltd www.oncosil.com.au T: +61 2 9223 3344 F: +61 2 9252 3988 OncoSil Medical 24